Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine

Vaccine

Volumn 29, Issue 15, 2011, Pages 2720-2726

  Miyata, Takeshi ^a   Harakuni, Tetsuya ^a   Sugawa, Hideki ^a,b   Sattabongkot, Jetsumon ^c   Kato, Aki ^d   Tachibana, Mayumi ^e   Torii, Motomi ^e   Tsuboi, Takafumi ^d   Arakawa, Takeshi ^a,e  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b AMBiS Corporation   (Japan)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d EHIME UNIVERSITY   (Japan)

^e EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Human adenovirus; Malaria transmission blocking vaccine

Indexed keywords

ADENOVIRUS VECTOR; ADPVS25; ALUMINUM HYDROXIDE; FREUND ADJUVANT; IMMUNOGLOBULIN G; MALARIA VACCINE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN ADENOVIRUS 5; IMMUNIZATION; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, VIVAX; MICE; MICE, INBRED BALB C; THAILAND; VACCINATION; VACCINES, SYNTHETIC;

EID: 79952245805     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.083     Document Type: Article

References (38)

1. WHO. World Health Report. 2008.
2. Greenwood B.M., Fidock D.A., Kyle D.E., Kappe S.H., Alonso P.L., Collins F.H., et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008, 118(4 (April)):1266-1276.
3. Targett G.A., Greenwood B.M. Malaria vaccines and their potential role in the elimination of malaria. Malar J 2008, 7(Suppl. 1):S10.
4. Genton B. Malaria vaccines: a toy for travelers or a tool for eradication?. Expert Rev Vaccines 2008, 7(5 (July)):597-611.
5. PATH malaria vaccine initiative: about the malaria vaccine roadmap. Available from: http://www.malariavaccineorg/malvac-roadmap.php.
6. Sharma S., Pathak S. Malaria vaccine: a current perspective. J Vector Borne Dis 2008, 45(1 (March)):1-20.
7. WHO. Malaria vaccine rainbow tables. Available from: http://www.who.int/vaccine_research/links/Rainbow/en/index.html.
8. Ballou W.R. The development of the RTS, S malaria vaccine candidate: challenges and lessons. Parasite Immunol 2009, 31(9 (September)):492-500.
9. Richards J.S., Beeson J.G. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009, 87(5 (July)):377-390.
10. Tsuboi T., Tachibana M., Kaneko O., Torii M. Transmission-blocking vaccine of vivax malaria. Parasitol Int 2003, 52(1 (March)):1-11.
11. Kaslow D.C. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol 1997, 27(2 (February)):183-189.
12. Carter R. Transmission blocking malaria vaccines. Vaccine 2001, 19(17-19 (March)):2309-2314.
13. Arevalo-Herrera M., Chitnis C., Herrera S. Current status of Plasmodium vivax vaccine. Hum Vaccin 2010, 6(1 (January)).
14. Birkett A.J. PATH malaria vaccine initiative (MVI): perspectives on the status of malaria vaccine development. Hum vaccin 2010, 6(1 (January)):139-145.
15. Sina B. Focus on Plasmodium vivax. Trends Parasitol 2002, 18(7 (July)):287-289.
16. Kochar D.K., Das A., Kochar S.K., Saxena V., Sirohi P., Garg S., et al. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg 2009, 80(2 (February)):194-198.
17. Bill and Melinda Foundation. Global Health Program. Available from: http://www.gatesfoundation.org/global-health/Documents/malaria-strategy.pdf.
18. Herrington D.A., Nardin E.H., Losonsky G., Bathurst I.C., Barr P.J., Hollingdale M.R., et al. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. Am J Trop Med Hyg 1991, 45(6 (December)):695-701.
19. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23(24 (May)):3131-3138.
20. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 3(7):e2636.
21. Li S., Locke E., Bruder J., Clarke D., Doolan D.L., Havenga M.J., et al. Viral vectors for malaria vaccine development. Vaccine 2007, 25(14 (March)):2567-2574.
22. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8(1 (January)):62-73.
23. Limbach K.J., Richie T.L. Viral vectors in malaria vaccine development. Parasite Immunol 2009, 31(9 (September)):501-519.
24. Reyes-Sandoval A., Harty J.T., Todryk S.M. Viral vector vaccines make memory T cells against malaria. Immunology 2007, 121(2 (June)):158-165.
25. Beeson J.G., Osier F.H., Engwerda C.R. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol 2008, 24(12 (December)):578-584.
26. Russell K.L., Hawksworth A.W., Ryan M.A., Strickler J., Irvine M., Hansen C.J., et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine 2006, 24(15 (April)):2835-2842.
27. Miyata T., Harakuni T., Tsuboi T., Sattabongkot J., Kohama H., Tachibana M., et al. Plasmodium vivax ookinete surface protein, Pvs25, linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect Immun 2010.
28. Arakawa T., Komesu A., Otsuki H., Sattabongkot J., Udomsangpetch R., Matsumoto Y., et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun 2005, 73(11 (November)):7375-7380.
29. Arakawa T., Tsuboi T., Kishimoto A., Sattabongkot J., Suwanabun N., Rungruang T., et al. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 2003, 21(23 (July)):3143-3148.
30. Arakawa T., Tachibana M., Miyata T., Harakuni T., Kohama H., Matsumoto Y., et al. Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection. Infect Immun 2009, 77(12 (December)):5496-5500.
31. Kass-Eisler A., Li K., Leinwand L.A. Prospects for gene therapy with direct injection of polynucleotides. Ann NY Acad Sci 1995, 772(November):232-240.
32. Suwanabun N., Sattabongkot J., Tsuboi T., Torii M., Maneechai N., Rachapaew N., et al. Development of a method for the in vitro production of Plasmodium vivax ookinetes. J Parasitol 2001, 87(4 (August)):928-930.
33. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003, 2(9 (September)):727-735.
34. Kongkasuriyachai D., Bartels-Andrews L., Stowers A., Collins W.E., Sullivan J., Sattabongkot J., et al. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 2004, 22(23-24 (August)):3205-3213.
35. Coban C., Philipp M.T., Purcell J.E., Keister D.B., Okulate M., Martin D.S., et al. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun 2004, 72(1 (January)):253-259.
36. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010, 78(1 (January)):145-153.
37. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum vaccin 2010, 6(1 (January)).
38. Bruna-Romero O., Gonzalez-Aseguinolaza G., Hafalla J.C., Tsuji M., Nussenzweig R.S. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 2001, 98(20 (September)):11491-11496.